<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005234</url>
  </required_header>
  <id_info>
    <org_study_id>GFH925X1101</org_study_id>
    <nct_id>NCT05005234</nct_id>
  </id_info>
  <brief_title>A Study of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations</brief_title>
  <official_title>An Open-label, Multi-center Phase I/II Clinical Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Effectiveness of GFH925 in Patients With Advanced Solid Tumors With KRAS G12C Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Genfleet Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfleet Therapeutics (Shanghai) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I: To evaluate the safety and tolerability of GFH925 in subjects with KRAS G12C mutant&#xD;
      advanced solid tumors and estimate the maximum tolerated dose (MTD) and/or a recommended&#xD;
      phase 2 dose (RP2D).Phase II: To evaluate the efficacy of GFH925 in subjects with KRAS G12C&#xD;
      mutant advanced non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 10, 2021</start_date>
  <completion_date type="Anticipated">April 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with dose-limiting toxicities (DLTs)</measure>
    <time_frame>Baseline to 24 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) as assessed by RECIST 1.1 criteria</measure>
    <time_frame>Baseline to 24 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>KRAS G12C</condition>
  <arm_group>
    <arm_group_label>GFH925</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I Dose Escalation Subjects with advanced NSCLC and gastrointestinal tumors will be enrolled in dose escalation cohorts based on Bayesian optimal interval (BOIN) design.&#xD;
Phase I Dose Expansion Upon completing the dose exploration part of the study and depending on data obtained, dose expansion may proceed with responsive groups consisting of subjects with KRAS G12C mutant advanced NSCLC. Dose expansion may be done concurrently.&#xD;
Phase 2 Subjects with advanced NSCLC will be enrolled and treated at the monotherapy RP2D to evaluate the safety and efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GFH925</intervention_name>
    <description>Administered as an oral tablet formulation</description>
    <arm_group_label>GFH925</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women â‰¥18 years old&#xD;
&#xD;
          -  Pathologically diagnosed, previously treated, advanced tumor with KRAS p.G12C mutation&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1 criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant concomitant diseases&#xD;
&#xD;
          -  Active brain metastases&#xD;
&#xD;
          -  Previous treatment with KRAS G12C inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Li</last_name>
    <phone>+86 21 6882 1388</phone>
    <email>yli@genfleet.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2021</study_first_posted>
  <last_update_submitted>August 8, 2021</last_update_submitted>
  <last_update_submitted_qc>August 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

